All In Biotech

Drug Trial Radar · NCT03254628

Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation

Last checked: Nov 19, 2026Latest source record: Aug 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,440

Actual

Start

Nov 14, 2014

Primary completion

Dec 31, 2016

Study completion Dec 31, 2016

Sponsor

Lead sponsor
JhpiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Agency for International Development (USAID)
First posted
Aug 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims are to evaluate the impact of supportive follow-up strategies for a novel twinned training and capacity-sustaining program among frontline health workers (providers) attending facility-based births in remote and district level health facilities in Uganda. The program is designed to improve provider competencies, provider performance and health outcomes among women giving birth and newborns.

Conditions

  • Postpartum Hemorrhage
  • Neonatal Asphyxia

Interventions

  • Helping Mothers Survive - Bleeding After Birth trainingOther

    One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.

  • Helping Babies BreatheOther

    One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.

  • MentorBehavioral

    A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.

  • PhoneBehavioral

    District trainers telephone clinical mentors and encourage them to lead practice sessions.

  • oxytocin and misoprostolDrug

    This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.

  • Newborn bag and maskDevice

    All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in differences: change in use of oxytocin for prevention of postpartum hemorrhageTime frame: Baseline, Midline (6 months), Endline (12 months)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.